January 2020 updates to the website

The website has now been updated following January's LSCMMG/JCCCGs

The following drugs have been added/updated:

Cariprazine (Reagila ®) — Treatment of schizophrenia in adult patients

Lanreotide — Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Ocreotide — Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Cyanocobalamin — Treatment of: nutritional Vitamin B12 deficiency; vitamin B 12 deficiency following partial gastrectomy; tropical sprue, alone or with folic acid; pernicious anaemia

Azathioprine ‑ For treatment of Myasthenia Gravis

Pentosan polysulfate sodium - for treating bladder pain (NICE TA610)

Fluocinolone acetonide intravitreal implant - For treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (NICE TA613)

The following guidelines have been added/updated:

Dementia Information Sheet (Version 1.6) - Updated

Riluzole Information Sheet (Version 2.1) - Updated

The following Items will be ratified and added to the website following March’s Joint Committee of CCGs (JCCCG) Meeting:

Octreotide - Secretory gastrointestinal disorders

Lanreotide - Secretory gastrointestinal disorders

Oscillating Positive Expiratory Pressure Devices - For Non – Cystic Fibrosis Bronchiectasis

Agomelatine - For the Treatment of Major Depressive Episodes in Adults